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a Preparative Regimen Before Allogeneic
Hematopoietic Stem Cell Transplantation for Adult
Patients with Acute Lymphoblastic Leukemia
Wei Tang, Ling Wang, Wei-Li Zhao, Yu-Bao Chen, Zhi-Xiang Shen, Jiong HuThe use of i.v. busulfan (BU) instead of the oral formulation can improve outcomes in patients undergoing
allogeneic hematopoietic stem cell transplantation (allo-HSCT) by reducing toxicity and transplantation-atology, Shanghai Institute of Hematology, Rui Jin Hospital, Shang-
lantation Center, Department of Hematology, Shanghai Institute of
of Medicine, 18F/OPD Bldg, 197 Rui Jin Road II, Shanghai 200025,
1556 Biol Blood Marrow Transplant 17:1546-1568, 2011W. Tang et al.related mortality (TRM). There are limited reports of i.v. BU used to treat patients with acute lymphoblastic
leukemia (ALL). The present study was performed to evaluate the efficacy and toxicity of i.v. BU/cyclophos-
phamide (CY) conditioning in adult ALL. We retrospectively analyzed 42 consecutive patients who
underwent allo-HSCT with BU/CY conditioning between January 2007 and October 2010 with an HLA-
matched donor (sibling, n 5 18; unrelated, n 5 24). Thirty-three patients were in first complete remission
(CR1), 2 were in second complete remission (CR2), and 7 were in a more advanced stage. Median patient age
was 28 years (range, 1755 years). The median follow-up was 15 months (range, 148 months). Overall,
13 patients died, for a 30-month overall survival of 56.5% 6 10.6% (65.7% 6 12.5% for patients in CR1 vs
25.4% 6 15.5% for those in CR2 or beyond; P\ .001). Eleven patients experienced relapse between 2
and 26 months after allo-HSCT, with a 30-month relapse rate (RR) of 40%6 10.9% (32.0%6 12.7% for pa-
tients in CR1 vs 71.4% 6 17.1% for those in CR2 or beyond; P 5 .001). The incidence of grade II-IV acute
graft-versus-host disease (GVHD) was 39.2% 6 8.8%, and that of grade III-IV acute GVHD was 7.4% 6
4.1%. The incidence of chronic GVHD was 63.9% 6 11.7%, and that of extensive chronic GVHD was
19.3% 6 7.9%. Only 2 cases of clinically diagnosed veno-occlusive disease (VOD) were documented
(4.7%), and 1 of these patients died of severe VOD. Other BU/CY conditioning–associated toxicities were
diffuse alveolar hemorrhage in 1 patient and hemorrhagic cystitis in 8 patients. Four patients died due to
TRM, for a 30-month TRM of 9.7%6 4.6%. This study demonstrates that i.v. BU/CY can be considered a fea-
sible conditioning regimen for adult ALL, with low incidences of VOD and TRM.
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The selection of conditioning regimen for
allogeneic hematopoietic stem cell transplantation
(allo-HSCT) should be optimized to provide the
maximal antileukemic effect with minimal toxicity.
Combinations of cyclophosphamide (CY) with total
body irradiation (TBI) or busulfan (BU) have been
used for more than 20 years as conditioning regimens
for various hematologic malignancies [1-3]. TBI has
the advantage of eradicating leukemic cells of the
central nervous system or testicles as ‘‘sanctuary
sites’’ [4]. BU is an alkylating agent commonly used
in high-dose chemotherapy regimens, which offered
the advantage of easier administration and a lack of
the toxicity associated with TBI, including interstitial
pneumonitis, cataract, growth retardation, and other
endocrine disturbances [4,5]. A BU-based regimen
has proven superior for treating chronic myelogenous
leukemia (CML), whereas a TBI-based regimen has
been shown to be superior for treating acute myeloge-
nous leukemia (AML), in terms of lower leukemia
relapse and transplantation-related mortality (TRM)
[6-9]. For acute lymphoblastic leukemia (ALL), the
available data are controversial, based on the limited
number of patients reported [10]. In a recent meta-
analysis, BU/CY regimens were associated with higher
TRM but a similar relapse rate compared with
TBI/CY regimens [11]. BU/CY regimens also are
associated with more complications, including liver
veno-occlusive disease (VOD) and hemorrhagic
cystitis [11-13]. In pediatric patients, the main cause
of inferior outcomes with BU/CY regimens is the
higher mortality rate [14]. Of note, most of these stud-
ies compared TBI/CY and oral BU/CY regimens,characterized by wide interpatient and intrapatient
variability in pharmacokinetics. Currently used i.v.
BU formulations have more reliable and consistent
pharmacokinetics [5]. In previous studies, the i.v.
BU/CY was associated with decreased incidence of
VOD, VOD-related mortality, and overall 100-day
mortality [15,16]. There are limited published reports
on the role of i.v. BU/CY as a conditioning regimen
for ALL. Here we report the clinical outcomes in
adult patients with ALL undergoing allo-HSCT
from HLA-matched sibling or unrelated donors.PATIENTS AND METHODS
Patients and Eligibility Criteria for Allo-HSCT
This study retrospectively analyzed the outcomes
of 42 consecutive adult patients with ALL who under-
went allo-HSCT between January 2007 and October
2010 in the Blood and Marrow Transplantation
Center of Rui Jin Hospital, Shanghai Jiao Tong
University School of Medicine. Eligibility criteria
for allo-HSCT were as follows: either an HLA-
matched sibling or an unrelated donor available,
performance status \2, normal renal and hepatic
function (serum creatinine #1.5 mg/100 mL, serum
bilirubin #1.0 mg/100 mL, serum glutamic-pyruvic
transaminase #3 times the upper normal limit),
cardiac left ventricular ejection fraction $50%,
normal pulmonary function tests (including forced
expiratory volume in 1 minute), and negative serology
for hepatitis B and human immunodeficiency virus.
All patients provided written informed consent to
undergo allo-HSCT.




ge, years, median (range) 28 (1755)
onor type, n
HLA-matched sibling 18
HLA-matched unrelated donor 24
isease stage, n
CR1 33 (Ph+ ALL, 7)
CR2 2 (Ph+ ALL, 1)




ollow-up, months, median (range) 15 (148)
Biol Blood Marrow Transplant 17:1546-1568, 2011 1557i.v. Bu-Cy as a Preparative Regimen Before allo-HSCTConditioning Regimen
Patients received i.v. BU (Busulfex) at 1.6 mg/kg
every 12 hours for 8 doses over 4 days (from day –7
to day –4 before allo-HSCT). The i.v. BU dose was
based on actual body weight and was administered by
infusion over 4 hours [17]. The i.v. BU was followed
by CY 60 mg/kg/day i.v. over 4 hours for 2 days
(days –3 and –2). Allogeneic bone marrow or periph-
eral blood stem cells were infused on day 0, followed
by granulocyte colony-stimulating factor 5 mg/kg i.v.
starting on day13 after allo-HSCT until the absolute
neutrophil count exceeded 0.5  109/L. Graft-versus-
host disease (GVHD) prophylaxis consisted of
cyclosporine 1.5 mg/kg twice daily via continuous
i.v. infusion, with a switch to the oral formulation if
tolerated. The cyclosporine dose was adjusted to
a therapeutic level of 200250 mg/mL. In addition,
methotrexate was given at doses of 15 mg/m2 on day
11 and 10 mg/m2 on days 13, 16 and 111, and
mycophenolate mofetil 1.0 g was given twice daily
from day 11 to day 130. Antithymocyte globulin
rabbit (Thymoglobulin; Genzyme, Cambridge, MA)
at a total dose of 6 mg/kg was given from day –4 to
day –1 to patients undergoing allo-HSCT from an
unrelated donor.
Supportive Care
Phenytoin was administered as seizure prophylaxis
before and during BU treatment in all patients. For
VOD prophylaxis, lipo-prostaglandin E1 (lipo-PGE1)
0.5 mg/kg was given regularly at the start of
conditioning until day121. Mesna, antiemetics, blood
components, and other supportive care measures
were provided according to institutional guidelines.
Toxicity
The definition of VOD used in the present study
was based on the Seattle clinical criteria [18], with
a diagnosis of VOD requiring at least 2 of the
following within 20 days of transplantation: serum
bilirubin .2 mg/dL (34 mM/L), hepatomegaly, and
weight gain .5% over baseline. VOD was classified
as mild, moderate, or severe. Mild VOD was defined
as the absence of adverse effects of liver dysfunction
with complete resolution of symptoms and signs.
Moderate VOD was defined as adverse effects of liver
dysfunction requiring therapy, such as diuretics for
fluid retention and analgesics for pain. Severe VOD
was defined as the persistence of symptoms after day
100 or death before day 100 with ongoing VOD. Acute
GVHD (aGVHD) and chronic GVHD (cGVHD)
were diagnosed and graded accordingly [19,20].
Statistical Analysis
The outcomes of allo-HSCT are presented in






F(EFS), relapse rate (RR), TRM, and regimen-related
toxicities. The probabilities of leukemia relapse and
TRMwere calculated using cumulative incidence esti-
mates. Survival rates were calculated using Kaplan-
Meier estimates. Univariate comparisons were
performed using the log-rank test [21]. For analysis
of OS, failure was defined as the time of death from
any cause. For analysis of TRM, failure was defined
as death occurring while the patient was in continuous
complete remission (CR). For analysis of relapse, fail-
ure was defined as clinical or hematologic recurrence
of ALL at any site. For analysis of EFS, treatment
was considered to have failed at the time of clinical
or hematologic relapse at any site or at the time of
death from any cause. Data for patients who were
alive and in CR were censored at the time of the last
follow-up visit.RESULTS
Patients and Characteristics
A total of 42 patients were included in the analysis.
Demographic data for these patients are summarized
in Table 1. The median patient age was 28 years
(range, 1755 years). Thirty-three patients were in
first CR (CR1), 2 were in second CR (CR2), and 7
were in a more advanced stage (refractory/relapse).
Twenty-four patients underwent allo-HSCT with an
HLA-matched unrelated donor, and 18 patients
underwent allo-HSCT with an HLA-matched sibling
donor. The stem sell source was peripheral blood
stem cells in 39 patients and bone marrow in 3
patients. The median follow-up was 15 months (range,
148 months).Engraftment and Chimerism
For all 42 patients, the median number of
mononucleated cells and CD34 cells infused was
5.0  108/kg (range, 1.78.9  108/kg) and 4.9 
106/kg (range, 1.015.6  106/kg), respectively.
Figure 1. A, OS of patients undergoing allo-HSCTwith an i.v. BU/CY
regimen. The 30-month OS after allo-HSCT was 65.3% 6 12.5% for
patients undergoing transplantation while in CR1 and 25.4% 6 15.5%
for those undergoing transplantation in CR2 or a more advanced stage
(P\.001). B, EFS of patients undergoing allo-HSCTwith an i.v. BU/CY
regimen. The 30-month EFS was 63.4%6 12.3% for patients undergoing
transplantation while in CR1 and 25.4% 6 15.5% for those undergoing
transplantation in CR2 or a more advanced stage (P 5 .001). C, RR of
patients undergoing allo-HSCT with an i.v. BU/CY regimen. The
30-month RR after allo-HSCTwas 32.0%6 12.7% for patients undergo-
ing transplantation while in CR1 and 71.4%6 17.1% in those undergoing
transplantation in CR2 or a more advanced stage (P 5 .001).
1558 Biol Blood Marrow Transplant 17:1546-1568, 2011W. Tang et al.Neutrophil engraftment (ie, absolute neutrophil
count $0.5  109/L) occurred in all 42 patients, at
a median of 13 days (range, 723 days), and the me-
dian time of platelet recovery (ie, $20  109/L) was
17 days (range, 961 days) in 41 patients. One patient
died of VOD on day129 before the documentation of
platelet engraftment. The development of donor-
derived hematopoiesis was further documented by
short tandem repeat polymerase chain reaction, and
all 41 evaluable patients achieved 100% donor type
on day 128 to 130 posttransplantation.
OS and EFS
A total of 13 patients died during follow-up, for an
overall estimated 30-month OS of 56.5% 6 10.6%.
Patients who underwent transplantation while in
CR1 had superior outcomes, with a 30-month OS of
65.7% 6 12.5% (median not reached), compared
with 25.4% 6 15.5% (median, 6 months; P\ .001)
(Figure 1A) for patients who underwent transplanta-
tion while in CR2 or beyond. The overall 30-month
EFS was 55.2% 6 10.4%; EFS was 63.4% 6 12.3%
(median not reached) in patients undergoing trans-
plantation while in CR1, compared with 25.4% 6
15.5% (median, 3 months) in patients in CR2 or
beyond (P 5 .001) (Figure 1B).
Relapse after Allo-HSCT
Eleven patients relapsed at 2-26 months after allo-
HSCT, with an overall accumulated 30-month RR of
40.0% 6 10.9%. Five of 9 patients who underwent
transplantation while in CR2 or beyond relapsed
(RR, 71.4%6 17.1%), compared with 6 of 33 patients
in CR1 (RR, 32.0%6 12.7%) (Figure 1C). Among the
patients in CR1, 5 relapse events occurred within the
first 12 months posttransplantation (range, 2-10
months); only 1 patient relapsed at 26 months after
transplantation from an unrelated donor with persis-
tent chronic GVHD. All 5 patients undergoing all-
HSCTwhile in a more advanced disease stage relapsed
within 6 months posttransplantation. Of note, among
all the relapse events, only 1 patient developed relapse
in the testis, with subsequent bone marrow relapse 3
months after orchiectomy and radiation therapy.
Treatment-Related Toxicity and TRM
Fourteen of 41 evaluable patients developed grade
II-IV aGVHD, with an overall incidence of 39.2% 6
8.8% (25.9%6 11.7% for patients with a sibling donor
and 50.2%6 12.6% for those with an unrelated donor;
P 5 .11). Only 3 patients had grade III-IV aGVHD,
with an overall incidence of 7.4% 6 4.1% (5.6% 6
5.4% for patients with a sibling donor and 8.9% 6
6.0% for those with an unrelated donor; P 5 .67).
During follow-up, the overall incidence of cGVHD
in 33 evaluable patients was 63.9% 6 11.7% (77.1%
Table 2. Impact of Disease Stage on Outcome of Allo-HSCT
CR1 $CR2 P Value
Number of patients 33 9
30-month OS 65.7% ± 12.5% 25.4% ± 15.5% <.001
30-month EFS 63.4% ± 12.3% 25.4% ± 15.5% .001
30-month RR 32.0% ± 12.7% 71.4% ± 17.1% .001
30-month TRM 6.4% ± 4.4% 22.2% ± 13.9% .13
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6 18.0% for those with a sibling donor; P5 .066). The
incidence of extensive cGVHD was 19.3% 6 7.9%
(11.1% 6 10.5% for patients with a sibling donor vs
28.6% 6 12.1% for those with an unrelated donor;
P 5 .14).
For conditioning regimen–related toxicity, we
documented 1 case of mild VOD and 1 case of severe
VOD, for an overall incidence of 4.7%. The other tox-
icity included 1 case of diffuse alveolar hemorrhage
and 8 cases of hemorrhagic cystitis. Four patients
died due to transplantation toxicity; of these, 3 died
within 100 days posttransplantation, with an overall
30-month TRM of 9.7%6 4.6%. The causes of death
were VOD (n 5 1), grade IV aGVHD (n 5 1), diffuse
alveolar hemorrhage (n5 1), and pulmonary infection
after treatment for grade III aGVHD (n 5 1).
Prognostic Factors
We further analyzed the potential prognostic fac-
tors associated with clinical outcome. Although based
on a limited number of patients, disease stage at trans-
plantation was significantly associated with OS, EFS,
and RR, but not with TRM, on univariate analysis.
For patients undergoing transplantation while in
CR1, either donor type (sibling vs unrelated) or the
presence of the Philadelphia chromosome was not as-
sociated with OS, EFS, RR, or TRM (Tables 2 and 3).DISCUSSION
Analysis of results from large-scale clinical trials
demonstrates the important role of allo-HSCT with
HLA-matched sibling or unrelated donors in the
treatment of adult ALL [22,23]. Combinations of CY
with TBI or BU were the standard conditioning
regimens for decades. For ALL, TBI/CY has
remained a preferred regimen because of its benefit inTable 3. Prognostic Analysis for Transplantation Outcome in Patie
n 30-Month OS
Donor type 14
Sibling 14 81.8% ± 11.6%
Unrelated 19 55.5% ± 18.2%
Philadelphia chromosome status
Ph2 26 59.3% ± 15.6%
Ph+ 7 85.7% ± 13.2%controlling ‘‘sanctuary site’’ leukemia and lower TRM
compared with conventional oral BU/CY regimens
[4,10]. A recent meta-analysis including more than
800 patients with ALL showed that oral BU/CY
regimens were associated with lower EFS (P\ .001),
similar leukemia relapse (P 5 .42), and higher TRM
than TBI/CY regimens [11]. The BU/CY regimen
also was associated with higher rates of VOD and
hemorrhagic cystitis [11]. It has been shown that BU
systemic exposure in terms of area under the plasma
concentration-versus-time curve (AUC) is associated
with BU toxicity, manifested as gastrointestinal toxicity,
hepatotoxicity, mucositis, and aGVHD with increasing
AUC [24]. The risk of death was significantly lower for
patients with a per-dose AUC of 9501520 mMol/min
compared with patients with either lower or higher
AUC values [24]. The complete bioavailability of i.v.
BU provides dose assurance by reducing interdose
and interpatient variability, which may decrease the
toxicity and TRM associated with oral formulations [5].
Kashyap et al. [15] reported a multiple-center
study of patients undergoing allo-HSCT in which
the incidence of clinically diagnosed VOD was 8%
(5/61) in patients receiving i.v. BU and 33% (10/30)
in those receiving oral BU. VOD-related mortality
was 3.3% (n 5 2) in the i.v. BU group and 20%
(n 5 6) in the oral BU group (P 5 .001). Oral BU
was associated with higher 100-day TRM (33% vs
13%; P5 .02). In a retrospective study of 236 patients
with leukemia and myelodysplastic syndrome,
aGVHD developed in 30.1% of patients overall, with
no difference between the oral BU group (29.8%)
and i.v. BU group (30.9%) [16]. Hepatic VOD was
significantly more prevalent in the oral BU group
(42.0% vs 18.2%; P 5 .001), as was severe VOD
(6.1% vs 0). Other regimen-associated toxicities,
including grade III-V gastrointestinal bleeding
(P5 .004), diarrhea (P5 .026), coagulation abnormal-
ities (P 5 .007), and metabolic abnormalities
(P 5 .042), were significantly less prevalent in the i.v.
BU group. The accumulated NRM was also lower
in the i.v. BU group than in the oral BU group
(13.8% vs 24.4%; P5 .048). In amatched-pair analysis
comparing outcomes in patients receiving i.v. BU/CY
in 4 clinical trials with Center for International Blood
and Marrow Transplant Research data for patients
receiving oral BU, the overall incidence of VOD ornts in CR1
30-Month EFS 30-Month RR 30-Month TRM
19
72.7% ± 13.4% 26.7% ± 14.1% 0
55.5% ± 18.2% 37.5% ± 19.8% 11.2% ± 7.5%
59.3% ± 15.6% 35.7% ± 16.5% 8.2% ± 5.6%
71.4% ± 17.1% 28.6% ± 17.1% 0
1560 Biol Blood Marrow Transplant 17:1546-1568, 2011W. Tang et al.mortality in the first 28 days was 4.6% (4/83) in the i.v.
BU patients and 20.3% (38/149) in the oral BU
patients (P\ .001). The 100-day TRM was 8.7% in
the i.v. BU patients and 22.5% in the oral BU patients
(P 5 .015). In logistic regression analysis, only oral
BU administration was a significant risk factor for
VOD [25].
Although the potential benefit of i.v. BU in the
conditioning regimen is known, there is little data on
direct comparisons of i.v. BU/CY regimens and oral
BU/CY or TBI/CY regimens, particularly in patients
with ALL. The present study was performed to
evaluate the efficacy and toxicity of i.v. BU/CY as
a conditioning regimen in adult ALL. We found that
i.v. BU/CY conditioning was associated with
promising survival (OS, 65.7% 6 12.5%; EFS,
63.4% 6 12.3%), suggesting that i.v. BU/CY may be
an acceptable option in patients with ALL in CR1.
This was due mostly to the low incidence of clinically
diagnosed VOD (\5%) as well as the low VOD-
related mortality and overall TRM (9.7%). The low
incidence of VODmight be attributed to the inclusion
of i.v. BU and prostaglandin E1 (PGE1) prophylaxis
in our protocol [26]. Although there is no effective
prophylactic treatment for VOD, several clinical trials
have tested various prophylactic strategies, including
low-dose heparin and PGE1. Some have reported
that lipo-PGE1 is an effective prophylaxis for VOD
[26,27]. A more recent study demonstrated that
prophylactic lipo-PGE1 might not necessarily de-
crease the incidence of VOD but might reduce the se-
verity of VOD; none of the 40 patients developed
severe VOD, leading to a low 100-day TRM [28].
Based on these data, the efficacy of preventing VOD
by replacing oral BU with i.v. BU combined with
PGE1 prophylaxis can be considered confirmed in
a clinical trial. Although we used standard doses of
i.v. BU in the preparation regimen, another explana-
tion for the low TRM may be the possible low AUC
value of BU. Pharmacokinetic studies of i.v. BU from
Korea [29] and Japan [30] found similar pharmacoki-
netic profiles of i.v. BU as have been reported inWest-
ern countries. Of even more interest, the Japanese
study found high interpatient and intrapatient consis-
tency of i.v. BU pharmacokinetics, which might possi-
bly preclude the need for monitoring [30].
Unfortunately, there are no data available for i.v. BU
in the Chinese population; based on the foregoing
findings, studies of i.v. BU in the Chinese population
are needed to provide key information on i.v. BU phar-
macokinetics, whichmight help determine an ideal BU
dose to ensure antileukemia efficacy and low toxicity,
as demonstrated by several groups undergoing allo-
HSCTwith BU-based conditioning regimens [31-33].
Leukemia relapse remains the leading cause of
failure of allo-HSCT [10]. The RR is similar with
different conditioning regimens for ALL. In our series,leukemia relapse occurred in 32% of the patients who
underwent transplantation while in CR1. Most
relapses occurred within the first 12 months after
allo-HSCT; only 1 patient relapsed at 26 months
posttransplantation. For patients who underwent
transplantation in a more advanced disease stage, all
relapses occurred very early after transplantation. OS
was 65% for patients undergoing allo-HSCT while
in CR1, compared with only 25% for those undergo-
ing allo-HSCT in a more advanced disease stage.
This observation suggests that for patients in CR1,
i.v. BU/CY can be a feasible and effective conditioning
regimen, with leukemia RRs comparable to previous
reports, ranging from 22% to 37% in standard or
high-risk ALL [22,23,34]. Given the relatively short
follow-up in the present study, long-term observation
is warranted to confirm the benefit of i.v. BU/CY
regimens for patients undergoing allo-HSCT while
in CR1. As for salvage therapy for patients with more
advanced ALL, allo-HSCT is unlikely to benefit
most patients, as has been shown in 2 large studies
[35,36]. On the other hand, at least i.v. On the other
hand, i.v. BU/CY was not an ideal regimen based on
such a high relapse rate with extremely short
median OS and EFS. Of note, relapse from an
extramedullary sanctuary site has been documented
in only 1 patient, thus indicated that the efficacy of
controling sanctuary site leukemia by BU/CY might
be comparable to TBI-based regimen.
The present study has revealed several important
findings. First, an i.v. BU/CY regimen in adult ALL
can be feasible with limited toxicity, particularly
a low incidence of VODwhen combined with prophy-
lactic PGE1. Second, the overall TRM of i.v. BU/CY
is low in patients in CR1, leading to improved OS.
Third, i.v. BU/CY regimens are not suitable for
advanced-stage ALL, because of a high relapse rate.
Randomized trials are warranted to confirm the
exact role of i.v. BU/CY conditioning regimens in
allo-HSCT for adult ALL.ACKNOWLEDGMENTS
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